STUDI PROFIL KADAR NT-proBNP SEBAGAI LANGKAH AWAL NT-ProBNP GUIDED THERAPY PADA PASIEN GAGAL JANTUNG AKUT

Rieka Nurul Dwi Anggraeni, Wenny Putri Nilamsari, Mochamad Yusuf Alsagaff, Dinda Monika Nusantara Ratri

Sari


Selain digunakan sebagai indikator signifikan untuk diagnosis klinis gagal jantung akut, pemeriksaan NT-proBNP juga dapat membantu menentukan tingkat keparahan, memandu strategi pengobatan yang relevan, dan menilai prognosis penyakit jantung. Dari penelitian yang sudah ada sebelumnya diketahui penerapan NT-proBNP guided therapy dapat menurunkan kadar NT-proBNP selama perawatan ≥ 30%. Penelitian ini bertujuan untuk menganalisis profil kadar NT-ProBNP sebagai Langkah awal dalam NT-proBNP guided therapy. Jenis penelitian ini adalah penelitian observasional dengan desain cross sectional. Pengambilan sampel dilakukan di IGD Rumah Sakit Universitas Airlangga selama periode Juni-Agustus 2023 dengan kriteria inklusi pasien AHF berusia ≥ 18 tahun dan didiagnosis AHF secara klinis dengan adanya satu gejala pada HF (dispnea, ortopnea, atau edema) dan satu tanda (rales, edema perifer, asites, atau kongesti vaskular paru pada radiografi dada. Pemeriksaan kadar NT-proBNP menggunakan prinsip Enzyme-Linked Immunosorbent Assay (ELISA) menggunakan metode Chemiluminescent Microparticle Immunoassay (CMI). Analisis data secara deskriptif menunjukkan hasil bahwa daei 39 pasien yang masuk ke dalam kriteria inklusi, terdapat 32 sampel dengan profil kadar NT-proBNP meningkat ≥ 300 pg/mL.

Kata Kunci


Gagal jantung akut, kadar NT-proBNP, NT-proBNP guided therapy

Teks Lengkap:

PDF

Referensi


Al Alawi, A.M., Al Busaidi, I., Al Shibli, E., Al-Senaidi, A.R., Al Manwari, S., Al Busaidi, I., Muhanna, F. and Al Qassabi, A., 2022. Health outcomes after acute ischemic stroke: retrospective and survival analysis from Oman. Annals of Saudi Medicine, 42(4), pp.269-275.

-

Born, M.C., Azzolin, K.D.O. and Souza, E.N.D., 2019. How long before hospital admission do the symptoms of heart failure decompensation arise?. Revista Latino-Americana de Enfermagem, 27, p.e3119.

-

Cao, Z., Jia, Y. and Zhu, B., 2019. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. International journal of molecular sciences, 20(8), p.1820.

-

Echouffo-Tcheugui, J.B., Zhang, S., McEvoy, J.W., Juraschek, S.P., Coresh, J., Christenson, R.H., Ndumele, C.E. and Selvin, E., 2023. Body Composition Measures and N-terminal pro-B-type Natriuretic Peptide (NT-pro-BNP) in US Adults. Clinical chemistry, 69(8), pp.901-914. Felker, G. M. et al., 2020. Diuretic Therapy for Patients With Heart Failure. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Volume 75, pp. 1178-1195.

-

Felker, G.M., Anstrom, K.J., Adams, K.F., Ezekowitz, J.A., Fiuzat, M., Houston-Miller, N., Januzzi, J.L., Mark, D.B., Piña, I.L., Passmore, G. and Whellan, D.J., 2017. Effect of natriuretic peptide–guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. Jama, 318(8), pp.713-720.

-

Lawson, C.A., Seidu, S., Zaccardi, F., McCann, G., Kadam, U.T., Davies, M.J., Lam, C.S., Heerspink, H.L. and Khunti, K., 2021. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine, 32.

-

McDonagh, T. et al., 2021. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the ESC With the special contribution of the Heart Failure Associatio. European Heart Journal, 42(36), pp. 3599-3726.

-

McLellan, J., Bankhead, C.R., Oke, J.L., Hobbs, F.R., Taylor, C.J. and Perera, R., 2020. Natriuretic peptide-guided treatment for heart failure: a systematic review and meta-analysis. BMJ Evidence-Based Medicine, 25(1), pp.33-37.

-

Meyer, T. E., 2022. UpToDate. [Online]

Available at: https://www.medilib.ir/uptodate/show/3497[Accessed 24 1 2023].

-

Mullens, W. et al., 2019. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, Issue doi:10.1002/ejhf.1369, pp. 1-18.

-

Muscari, A., Bianchi, G., Forti, P., Magalotti, D., Pandolfi, P., Zoli, M. and Pianoro Study Group, 2021. N-terminal pro B-type natriuretic peptide (NT-proBNP): a possible surrogate of biological age in the elderly people. Geroscience, 43, pp.845-857.

-

Raffaello, W. M. et al., 2021. Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?. RADCLIFFE CARDIOLOGY, Issue DOI: https://doi.org/10.15420/cfr.2020.20.

-

Reyes, E. et al., 2016. Heart failure across Asia: Same healthcare burden but differences in organization of care. International Journal of Cardiology, Volume 223, pp. 163-167.

-

Rørth, R., Jhund, P.S., Yilmaz, M.B., Kristensen, S.L., Welsh, P., Desai, A.S., Køber, L., Prescott, M.F., Rouleau, J.L., Solomon, S.D. and Swedberg, K., 2020. Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circulation: Heart Failure, 13(2), p.e006541.

-

Rubattu, S., Pagliaro, B., Pierelli, G., Santolamazza, C., Di Castro, S., Mennuni, S. and Volpe, M., 2014. Pathogenesis of target organ damage in hypertension: role of mitochondrial oxidative stress. International Journal of Molecular Sciences, 16(1), pp.823-839.

-

Savarese, G. & Lund, L., 2017. Global Public Health Burden of Heart Failure. Card Fail Rev, Volume 1, pp. 7-11.

-

Stienen, S., Salah, K., Moons, A.H., Bakx, A.L., van Pol, P., Kortz, R.M., Ferreira, J.P., Marques, I., Schroeder-Tanka, J.M., Keijer, J.T. and Bayés-Genis, A., 2018. NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?). Circulation, 137(16), pp.1671-1683.

-

Tromp, J., Paniagua, S.M., Lau, E.S., Allen, N.B., Blaha, M.J., Gansevoort, R.T., Hillege, H.L., Lee, D.E., Levy, D., Vasan, R.S. and Van Der Harst, P., 2021. Age dependent associations of risk factors with heart failure: pooled population based cohort study. Bmj, 372.

-

Vijay, K., Neuen, B.L. and Lerma, E.V., 2022. Heart failure in patients with diabetes and chronic kidney disease: challenges and opportunities. Cardiorenal Medicine, 12(1), pp.1-10.




DOI: http://dx.doi.org/10.52689/higea.v16i2.604

Refbacks

  • Saat ini tidak ada refbacks.


##submission.license.cc.by-nc-sa4.footer##

https://montes.da.upm.es/

https://csdmm.da.upm.es/

slot gacor hari ini